Last $19.65 USD
Change Today +0.48 / 2.50%
Volume 257.6K
As of 8:10 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

aratana therapeutics inc (PETX) Snapshot

Open
$19.04
Previous Close
$19.17
Day High
$19.72
Day Low
$18.55
52 Week High
03/5/14 - $22.54
52 Week Low
10/2/14 - $9.20
Market Cap
682.0M
Average Volume 10 Days
268.6K
EPS TTM
$-0.63
Shares Outstanding
34.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARATANA THERAPEUTICS INC (PETX)

Related News

No related news articles were found.

aratana therapeutics inc (PETX) Related Businessweek News

View More BusinessWeek News

aratana therapeutics inc (PETX) Details

Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, acquisition, development, and commercialization of biopharmaceutical products for cats, dogs, and other companion animals worldwide. Its product portfolio includes approximately 15 product candidates consisting of small molecule pharmaceuticals and large molecule biologics that target various opportunities in serious medical conditions in pets. The company develops AT-001, a prostaglandin E receptor 4 antagonist to treat the pain and inflammation associated with osteoarthritis in dogs, as well as for the management of pain in cats; AT-002, a ghrelin agonist for inappetence in cats and dogs; and AT-003, a bupivacaine liposome injectable suspension for the treatment of post-operative pain in cats and dogs. It also develops AT-004, a monoclonal antibody (MAB) used in the treatment of canine B-cell lymphoma; and AT-005, a MAB for the treatment of canine T-cell lymphoma in pets. The company was founded in 2010 and is headquartered in Kansas City, Kansas.

25 Employees
Last Reported Date: 03/26/14
Founded in 2010

aratana therapeutics inc (PETX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $50.7K
Chief Development Officer
Total Annual Compensation: $286.1K
Chief Commercial Officer
Total Annual Compensation: $270.6K
Chief Scientific Officer
Total Annual Compensation: $225.0K
Compensation as of Fiscal Year 2013.

aratana therapeutics inc (PETX) Key Developments

Aratana Therapeutics, Inc. - Special Call

Aratana Therapeutics, Inc. - Special Call

Aratana Therapeutics, Inc. Provides Product Updates

Aratana Therapeutics, Inc. provided several product updates. The company continues to advance its deep pipeline of novel therapeutics, including four products at pivotal stage (AT-001, AT-002, AT-003 and AT-014) and two products in post-approval marketing studies (AT-004 and AT-005). Aratana remains on track to achieve additional significant inflection points for its programs in 2015, including results from pivotal field effectiveness studies of AT-002 and AT-003, each in dogs.

Aratana Therapeutics, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 03:55 PM

Aratana Therapeutics, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 03:55 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Steven St. Peter, Co-Founder, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PETX:US $19.65 USD +0.48

PETX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Kindred Biosciences Inc $6.81 USD +0.09
View Industry Companies
 

Industry Analysis

PETX

Industry Average

Valuation PETX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 876.3x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 844.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARATANA THERAPEUTICS INC, please visit www.aratana.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.